Nippon Shinyaku Submits NDA For MDS Drug Azacitidine In Japan
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku Dec. 9 announced an NDA submission for NS-17 (azacitidine) for myelodysplastic syndrome with the Ministry of Health, Labor and Welfare